257 related articles for article (PubMed ID: 30671930)
21. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
Kim RH; Nagler AR; Meehan SA
J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
[No Abstract] [Full Text] [Related]
22. Muir-Torre syndrome.
Ponti G; Ponz de Leon M
Lancet Oncol; 2005 Dec; 6(12):980-7. PubMed ID: 16321766
[TBL] [Abstract][Full Text] [Related]
23. Muir-Torre syndrome: role of the dermatopathologist in diagnosis.
Curry ML; Eng W; Lund K; Paek D; Cockerell CJ
Am J Dermatopathol; 2004 Jun; 26(3):217-21. PubMed ID: 15166510
[TBL] [Abstract][Full Text] [Related]
24. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies.
Warschaw KE; Eble JN; Hood AF; Wolverton SE; Halling KC
J Cutan Pathol; 1997 Sep; 24(8):511-8. PubMed ID: 9331898
[TBL] [Abstract][Full Text] [Related]
25. A case of Muir-Torre syndrome with a keratoacanthoma and sebaceous neoplasms: Clinicopathological features and a speculation on the pathogenesis of cutaneous tumor type.
Takayama E; Yoshioka A; Takai T; Goto K
J Dermatol; 2021 May; 48(5):690-694. PubMed ID: 33523490
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
27. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
28. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
29. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
30. [Sebaceous tumors and Muir-Torre syndrome].
Bourlond F; Cribier B; Lipsker D; Velter C
Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836
[No Abstract] [Full Text] [Related]
31. Ocular Adnexal Adenomatoid Sebaceous Gland Hyperplasia: A Clinical and Immunopathologic Analysis in Relation to the Muir-Torre Syndrome.
Jakobiec FA; Cortes Barrantes P; Milman T; Lee NG; Fay A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):e6-e12. PubMed ID: 31593035
[TBL] [Abstract][Full Text] [Related]
32. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
33. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
34. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.
Arnold A; Payne S; Fisher S; Fricker D; Soloway J; White SM; Novelli M; MacDonald K; Mackay J; Groves R; Canham N
Fam Cancer; 2007; 6(3):317-21. PubMed ID: 17323113
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
36. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms.
Schwartz RA; Goldberg DJ; Mahmood F; DeJager RL; Lambert WC; Najem AZ; Cohen PJ
Dermatologica; 1989; 178(1):23-8. PubMed ID: 2917677
[TBL] [Abstract][Full Text] [Related]
37. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
38. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
39. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]